A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis

International Journal of Antimicrobial Agents

Volumn 13, Issue 4, 2000, Pages 243-248

  Yardley, Vanessa ^a   Croft, Simon L ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Amphotericin B; Leishmania; Lipid formulation; Macrophage

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY; STIBOGLUCONATE SODIUM;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; LIPOSOMES; MACROPHAGES; MESOCRICETUS; MICE; MICE, INBRED BALB C; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS;

EID: 0033980453     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00133-8     Document Type: Article

References (48)

1. Control of the leishmaniases. Report of a WHO Expert Committee. WHO Tech. Rep. Ser. 793:1990;50-55.
2. Berman J.D. Human leishmaniasis: clinical, diagnostic and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. 24:1997;684-703.
3. Cappucino E.F., Stauber L.A. Some compounds active against experimental leishmaniasis. Proc. Soc. Exp. Biol. Med. 101:1959;742-744.
4. Furtado T.A., Cisalpino E.O., Santos U.M. In vitro studies of the effect of amphotericin B on Leishmania braziliensis. Antibiot. Chemother. 10:1960;692-693.
5. Jha T.K., Giri Y.N., Singh T.K., Jha S. Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in North Bihar, India. Am. J. Trop. Med. Hyg. 52:1995;536-538.
6. Cohen B.E., Ramos H., Gamargo M., Urbina J. The water and ionic permeability induced by polyene antibiotices across plasma membrane vesicles from Leishmania spp. Biochim. Biophys. Acta. 860:1986;57-65.
7. Saha A.K., Mukherjee T., Bhadhuri A. Mechanism of action of amphotericin B on Leishmania donovani promastigotes. Mol. Biochem. Parasitol. 19:1986;195-200.
8. Beggs W.H. Physicochemical cell damage in relation to lethal amphotericin B action. Antimicrob. Agents Chemother. 38:1994;363-364.
9. Bolard J., Vertut-Doi A. Internalisation of amphotericin B and other polyene antifungals in mammalian cells: a possible origin of their toxicity. Georgopapdakou N.H. Drug Transport in Antimicrobial and Anticancer Chemotherapy. 1995;307 Marcel Dekker, NY.
10. Clements J.S. J.r, Peacock J.E. J.r Amphotericin B revisited: reassessment of toxicity. Am. J. Med. 88:1990;22-27.
11. Gregoriadis G. Overview of liposomes. J. Antimicrob. Chemother. 28((SB)):1991;39-48.
12. Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 13:1995;527-537.
13. Bakker-Woudenberg I.A.J.M., Storm G., Woodle M.C. Liposomes in the treatment of infection. J. Drug Target. 2:1994;363-371.
14. Hiemenz J.W., Walsh T.J. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22((S1)):1996;133-144.
15. Janknegt R., van Etten E.W.M., de Marie S. Lipid formulations of amphotericin B. Curr. Opin. Infect. Dis. 9:1996;403-406.
16. Berman J.D., Badaro R., Thakur C.P., Wasunna K.M., Bebehani K., Davidson R., Kuzoe F., Pang L., Weerasuriya K., Bryceson A.D.M. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull. WHO. 76:1998;25-32.
17. Dietze R., Fagundes S.M.S., Brito E.F., Feitosa T.T., Suassana F.A.B., Fonschiffrey G., Ksionski G., Dember J. Treatment of Brazilian kala-azar with a short course of Amphocil (amphotericin B cholesterol dispersion). Clin. Infect. Dis. 17:1995;981-986.
18. Sundar S., Murray H.W. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex. J. Infect. Dis. 173:1996;762-765.
19. Yardley V., Croft S.L. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob. Agents Chemother. 41:1997;752-756.
20. Sampaio S.A., Godoy J.T., Paiva L., Dillon N.L., Lacas C. da S. The treatment of American (mucocutaneous)leishmaniasis with amphotericin B. Arch. Dermatol. Syphilis, Wein. 82:1960;627-635.
21. Torre-Cisneros J., Prada J.L., Kindelan J.M., Jurado R., Sanchez-Guijo P. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 17:1994;625-627.
22. Mullen A.B., Carter K.C., Baillie A.J. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob. Agents Chemother. 41:1997;2089-2209.
23. Mullen A.B., Baillie A.J., Carter K.C. Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a non-ionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob. Agents Chemother. 42:1998;2722-2725.
24. Gangeux J.-P., Sulahian A., Garin Y. J.-F., Derouin F. Lipid formulations of amphotericin B in the treatment of experimental visceral leishmaniasis due to Leishmania infantum. Trans. R. Soc. Trop. Med. Hyg. 90:1996;574-577.
25. Neal R.A., Croft S.L. An in vitro system for determining the activity of compounds against the intracellular amastigote form of. J. Antimicrob. Chemother. 14:1984;463-475.
26. Allen S., Neal R.A. In vitro anti-Leishmanial activity of compounds in current clinical use for unrelated diseases. Drugs Exp. Clin. Res. 14:1989;621-628.
27. Brajtburg J., Bolard J. Carrier effects on biological activity of amphotericin B. Clin. Microbiol. Rev. 9:1996;512-531.
28. Legrand P., Vertut-Doi D., Bolard J. Comparative internalisation and recycling of different amphotericin B formulations by a macrophage-like cell line. J. Antimicrob. Chemother. 37:1996;519-533.
29. Wasan K.M., Lopez-Berestein G. Diversity of lipid-based polyene formulations and their behaviour in biological systems. Eur. J. Clin. Microbiol. Infect. Dis. 16:1997;81-92.
30. Yardley V., Croft S.L. In vitro and in vivo activity of amphotericin B-lipid formulations against experimental Trypanosoma cruzi infections. Am. J. Trop. Med. Hyg. 61:1999;193-197.
31. Hamanaka R., Seguchi T., Sato Y., Ono M., Kohno K., Kuwano M. Rapid turnover of low density lipoprotein receptor in human monocytic THP-1 cells. FEBS Lett. 294:1991;261-263.
32. Bhamra R., Sa'ad A., Bolcsak L.E., Janoff A.S., Swenson C.E. Behaviour of amphotericin B lipid complex in plasma in vitro and in the circulation of rats. Antimicrob. Agents Chemother. 41:1997;886-892.
33. Hart D.T. Leishmania host-parasite interactions: the development of chemotherapeutic targets and specific drug delivery systems. I. Lipoprotein mediated anti-leishmania chemotherapy. NATO ASI Series Vol H11. Host-parasite cellular and molecular infections. Chang K.-P., Snary D. Protozoal Infections. 1987;Springer-Verlag, Berlin, Germany.
34. van Etten E.W.M., Otte-Lambillion M., van Vianen W., ten Kate M.T., Bakker-Woudenberg I.A.J.M. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J. Antmicrob. Chemother. 35:1995;509-519.
35. Legrand P., Cheron M., Leroy L., Bolard J. Release of amphotericin B from delivery systems and its action against fungal and mammalian cells. J. Drug Target. 4:1997;311-319.
36. Wasan K.M., Rosenblum M.G., Cheung L., Lopez-Berestein G. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antmicrob. Agents Chemother. 38:1994;223-227.
37. Janknegt R., de Marie S., Bakker-Woudenberg I.A.J.M., Crommelin D.J.A. Liposomal and lipid formulations of amphotericin B. Clin. Pharmacokinet. 23:1992;279-291.
38. Heinemann V., Kähny B., Debus A., Wachholz K., Jehn U. Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations. Bone Marrow Transplant. 14:1994;S8-S9.
39. Heinemann V., Bosse D., Jehn U., Kähny B., Wachholz K., Debus A., Scholz P., Kolb H.-J., Wilmanns W. Pharmacokinetics of liposomal amphotericin B (AmBisome) in critically ill patients. Antimicrob. Agents Chemother. 41:1997;1275-1280.
40. New R.R.C., Chance M.L., Heath S. The treatment of experimental cutaneous leishmaniasis with liposome-entrapped pentostam. Parasitology. 83:1981;519-527.
41. Mirkovich A.M., Galelli A., Allison A.C., Moddaber F.Z. Increased myelopoiesis during Leishmania major infection in mice: generation of 'safe targets', a possible way to evade the effector immune system. Clin. Exp. Immunol. 64:1986;1-7.
42. Aebischer T., Moody S.F., Hardman E. Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host. Infect. Immunol. 61:1993;220-226.
43. McDonald P.J., Pruul H. Phagocyte uptake and transport of azithromycin. Eur. J. Clin. Microbiol. Infect. Dis. 10:1991;828-833.
44. Tohyama M., Kawakami K., Saito A. Anticryptococcal effect of amphotericin B is mediated through macrophage production of nitric oxide. Antimicrob. Agents Chemother. 40:1996;1919-1923.
45. Mozaffarian N., Berman J.W., Casadevall A. Enhancement of nitric oxide synthesis by macrophages represents and additional mechanism of action for amphotericin B. Antimicrob. Agents Chemother. 41:1997;1825-1829.
46. Russo R., Nigro L.C., Minniti S., Montineri A., Gradoni L., Caldeira L., Davidson R.N. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J. Infect. 32:1996;133-137.
47. Golenser J, Domb A, Ehrenfreund T, Frankenburg S, Rock P, Yardley V, Croft SL. New treatment for hemoflagellates using amphotericin B-arabinogalactan conjugates. IX International Congress of Parasitology 1998; Editors Tada I, Komija S, Tsuji M. Publisher Monduzi Editore Sp.A, Bologna, Italy, pp. 1285-1294.
48. Petit C., Yardley V., Gaboriau F., Bolard J., Croft S.L. Activity of a heat-induced reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovani. Antimicrob. Agents Chemother. 43:1999;390-392.